Medtronic and Novo Nordisk have entered an agreement to provide “integrated digital solutions” for people with diabetes, aiming to develop solutions enabling dosing data from Novo Nordisk smart insulin pens to be shared with Medtronic Continuous Glucose Monitoring devices.

The new collaboration will develop solutions to integrate insulin dosing data from future Novo Nordisk smart insulin pens into Continuous Glucose Monitoring (CGM) devices from Medtronic, such as the Guardian Connect system.

The news is welcome for patients with diabetes, as currently patients spend an average of one hour a day on self-care, amounting to a full two years devoted exclusively to their disease over their lifetime. However, the new, non-exclusive collaboration reflects both companies′ commitment to making diabetes management easier by integrating key health technologies.

By integrating glucose monitoring and insulin dosing data, people with diabetes and their healthcare professionals and caregivers - with permission from the person with diabetes - will be able to automatically track these two important items in a single place, giving people living with diabetes one less thing to think about in the daily management of their condition.

Further, being able to view both glucose and insulin data together can facilitate more productive conversations between people and their doctors, enabling more informed decisions on how to better manage glucose levels and increase Time in Range.

“Millions” of people living with diabetes “work to control their sugar levels and track their insulin injections every day. To help ease the hassle of diabetes management, we are excited to be partnering with Medtronic, the largest medical device company in the world,” said Camilla Sylvest, executive vice president, Commercial Strategy & Corporate Affairs, Novo Nordisk.

“We now collaborate with all major CGM device producers, which means we can bring the benefits of smart insulin pens to even more people.”

Novo Nordisk expects to launch its durable smart insulin pens, NovoPen6 and NovoPen Echo Plus, as well as its disposable, pre-filled injection solution starting in 2020.